This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
by Zacks Equity Research
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.
BSXNegative Net Change ISRGNegative Net Change HQYNegative Net Change MEDPNegative Net Change
medical medical-devices
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
by Zacks Equity Research
CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.
BSXNegative Net Change ISRGNegative Net Change MEDPNegative Net Change CODXNegative Net Change
medical medical-devices
KRMD Submits 510(k) to Use FreedomEDGE System With Oncology Biologic
by Zacks Equity Research
KORU Medical filed a 510(k) to use FreedomEDGE for subcutaneous PHESGO delivery, expanding into oncology and simplifying breast cancer care.
OMCLNegative Net Change KRMDPositive Net Change SDGRNegative Net Change CCLDNegative Net Change
medical medical-devices
ISRG Sees 91% SP Growth: A Turning Point for Single-Port Surgery?
by Indrajit Bandyopadhyay
ISRG's single-port platform posts 91% procedure growth, led by Korea, with U.S. momentum building as new tools and indications expand adoption.
SYKNegative Net Change ISRGNegative Net Change GMEDNegative Net Change
medical medical-devices
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
by Zacks Equity Research
CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.
BSXNegative Net Change CNMDNegative Net Change ISRGNegative Net Change IDXXNegative Net Change
medical medical-devices
How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?
by Moumi Mondal
BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.
BSXNegative Net Change JNJPositive Net Change MDTNegative Net Change
medical medical-devices
Best Growth Stocks to Buy for December 31st
by Zacks Equity Research
GLDD, CIEN and PODD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 31, 2025.
CIENNegative Net Change PODDNegative Net Change GLDDPositive Net Change
communications construction medical-devices
ESTA Shares Dip Despite FDA Filing for Motiva Breast Reconstruction
by Zacks Equity Research
Establishment Labs files Motiva breast implants with the FDA for reconstruction, targeting expansion beyond elective augmentation into a clinically necessary market.
BSXNegative Net Change ISRGNegative Net Change MEDPNegative Net Change ESTAPositive Net Change
medical medical-devices
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
by Debanjana Dey
Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.
TDOCNegative Net Change HIMSNegative Net Change LFMDNegative Net Change
medical medical-devices
RBOT Enters Strategic Software Partnership to Streamline Development
by Zacks Equity Research
Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.
EDAPPositive Net Change VCYTPositive Net Change RBOTPositive Net Change AORTPositive Net Change
medical medical-devices
Tilly's (TLYS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TLYSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Are Options Traders Betting on a Big Move in UFP Technologies Stock?
by Zacks Equity Research
Investors need to pay close attention to UFP Technologies stock based on the movements in the options market lately.
UFPTNegative Net Change
medical medical-devices
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
by Moumi Mondal
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
BSXNegative Net Change RMDNegative Net Change
medical medical-devices
Should Myriad Genetics Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.
ILMNNegative Net Change MYGNNegative Net Change PODDNegative Net Change BTSGNegative Net Change
medical medical-devices
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
by Indrajit Bandyopadhyay
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
RMDNegative Net Change MASINegative Net Change DXCMNegative Net Change
medical medical-devices
Reasons to Add Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO's revenues are showing strong growth as MyDay and MiSight drive momentum, while restructuring savings and buybacks bolster long-term upside despite near-term risks.
COONegative Net Change CORNegative Net Change PODDNegative Net Change PAHCNegative Net Change
medical medical-devices
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's strong Q3, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.
BSXNegative Net Change ISRGNegative Net Change VEEVPositive Net Change MEDPNegative Net Change
medical medical-devices
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
by Zacks Equity Research
OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
BSXNegative Net Change OMERPositive Net Change ATRCNegative Net Change PAHCNegative Net Change
medical medical-devices
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS appears well-positioned for long-term growth as iDose TR adoption accelerates and Epioxa secures FDA approval, although reimbursement and execution risks remain.
CORNegative Net Change PODDNegative Net Change PAHCNegative Net Change GKOSNegative Net Change
medical medical-devices
3 Medical Instrument Stocks to Counter Industry Woes Using GenAI
by Moumi Mondal
VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.
ISRGNegative Net Change IDXXNegative Net Change VCYTPositive Net Change
artificial-intelligence medical medical-devices
EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy
by Zacks Equity Research
Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.
EWNegative Net Change EDAPPositive Net Change VCYTPositive Net Change AORTPositive Net Change
medical medical-devices
Mitek Systems (MITK)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MITKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hologic's GYN Surgical Segment Looks Poised for Long-Term Growth
by Moumi Mondal
HOLX's GYN Surgical unit gains momentum as the demand for gynecological devices rises globally, driven by innovation, M&A and strong overseas adoption.
ABTNegative Net Change BDXNegative Net Change HOLXNo Net Change
medical medical-devices
Should You Continue to Hold BRKR Stock in Your Portfolio?
by Zacks Equity Research
Bruker's innovation pipeline and acquisitions support long-term growth, but macro pressures and funding risks cloud the stock's near-term outlook.
ILMNNegative Net Change PODDNegative Net Change BRKRNegative Net Change BTSGNegative Net Change
medical medical-devices
Reasons to Retain Baxter International Stock in Your Portfolio Now
by Zacks Equity Research
BAX is reshaping its portfolio following the divestiture of Kidney Care, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.
BAXNegative Net Change CORNegative Net Change PODDNegative Net Change PAHCNegative Net Change
medical medical-devices